Brief: Cymabay Therapeutics Presents Additional Analyses From Clinical Studies Of Seladelpar For Patients With Primary Biliary Cholangitis At The Liver Meeting 2022
04/11/2022 12:04
Nov 4 (Reuters) - Cymabay Therapeutics Inc CBAY.O :
* CYMABAY THERAPEUTICS PRESENTS ADDITIONAL ANALYSES FROM
CLINICAL
STUDIES OF SELADELPAR FOR PATIENTS WITH PRIMARY BILIARY
CHOLANGITIS AT THE LIVER MEETING® 2022
* CYMABAY THERAPEUTICS - AT 6 MONTHS, TREATMENT WITH
SELADELPAR
RESULTED IN SIGNIFICANT IMPROVEMENTS IN TOTAL CHOLESTEROL,
LDL-C, HDL-C, & TRIGLYCERIDES
* CYMABAY - COMPARISON OF LIPID LOWERING IN PATIENTS WITH &
WITHOUT CONCOMITANT LIPID THERAPY REVEALED SELADELPAR ACHIEVED
SIMILAR TREATMENT EFFECTS
Source text for Eikon: ID:nGNX4DGCBV
Further company coverage: CBAY.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on CymaBay Therapeutics
See all newsBrief: CymaBay Says EMA Accepted For Review The Marketing Authorization Application For Seladelpar
U.S. RESEARCH ROUNDUP-Bruker Corp, Cymabay Therapeutics, SSR Mining
U.S. RESEARCH ROUNDUP-An2 Therapeutics, Par Technology, Trimble
U.S. STOCKS ON THE MOVE-Perpetua Resources, Nvidia, SiriusXM
U.S. STOCKS ON THE MOVE-Lowe's, Bit Digital Snap